Conception is followed by a series of hormonal and metabolic changes that involve most maternal endocrine systems. With regard to thyroid metabolism, these include an increase in serum thyroxine-binding globulin and thyroid hormone concentrations, increased renal clearance of iodine, and increased production and turnover of thyroxine (T)
Thyroid Function in Pregnant Women
In pregnant women, renal clearance of iodide increases because of an increase in the glomerular filtration rate, and iodide and iodothyronines are transferred to the fetus. As a result, serum concentrations of inorganic iodide decrease. Women who live where iodine intake is marginal (<50 µg per day) may have an absolute or relative iodine deficiency and enlargement of the thyroid gland 3, 4, 5 . Even in areas of iodine sufficiency, such as the United States, the thyroid increases 10 to 20 percent in volume during pregnancy 4 . The fetus needs increasing amounts of iodide as fetal thyroid hormone production increases during the second half of gestation 1, 2 . In addition to transporting iodide across the placenta, monodeiodination of iodothyronines within the placenta provides increasing amounts of iodide to the fetus as the placenta enlarges.
Serum concentrations of thyroxine-binding globulin increase in pregnant women during the first trimester as a result of reduced clearance by the liver because of an estrogen-induced increase in sialylation of thyroxinebinding globulin and an estrogen-stimulated increase in its synthesis 6 . The concentration plateaus after 12 to 14 weeks of pregnancy and is associated with concomitant increases in serum total T 4 and triiodothyronine (T 3 ) concentrations ( Figure 1 ). Serum free T 4 concentrations increase slightly during the first trimester and then decrease. However, these changes are small, so that in most pregnant women serum free T 4 concentrations remain within the normal range for nonpregnant women 4, 7, 8 . The effects of pregnancy on the mother include a marked and early increase in hepatic production of thyroxine-binding globulin (TBG) and placental production of human chorionic gonadotropin (hCG). The increase in serum TBG, in turn, increases serum T 4 concentrations; hCG has thyrotropin-like activity and stimulates maternal T 4 secretion. The transient hCGinduced increase in serum free T 4 inhibits maternal secretion of thyrotropin.
T 4 requirements also increase during pregnancy. This is most evident in women with hypothyroidism who were treated with T 4 before becoming pregnant. In these women, the dose of T 4 has to be increased by 25 to 50 percent to maintain normal serum thyrotropin concentrations during the pregnancy 9, 10 . The specific reason for this increased need for T 4 is not known. The size of the extrathyroidal T 4 pool increases because of the increase in serum concentrations of thyroxine-binding globulin, but the increase amounts only to about 300 µg of T 4 and is largely achieved during the first trimester. Since the increased T 4 requirement is sustained until delivery, the increase in serum concentrations of thyroxine-binding globulin is unlikely to be the sole explanation. The increased requirement is probably also due to placental degradation of T 4 , the transfer of T 4 from mother to fetus, and increased maternal clearance of T 4 .
The negative-feedback control system of the hypothalamic-pituitary-thyroid axis functions normally in pregnant women, in that their serum thyrotropin concentrations during most of pregnancy are similar to those in nonpregnant women 7, 8 . In addition to the thyrotropin secreted by the maternal pituitary gland, the placenta produces large amounts of human chorionic gonadotropin, which has some thyrotropin-like bioactivity 11, 12 . The production of human chorionic gonadotropin begins during the first week after fertilization and is highest near the end of the first trimester, after which it declines. This increase causes a transient increase in serum free T 4 concentrations, which in turn decrease serum thyrotropin concentrations during the first trimester ( Figure 1 ) 11, 12 .
Maternal The Placenta
Metabolism of Iodothyronines
Three enzymes catalyze the deiodination of iodothyronines in human tissues 13 . Type I deiodinase, which catalyzes the deiodination of both the outer and inner rings, is a selenoprotein expressed in adults in liver, kidney, thyroid, and pituitary gland 14 . This enzyme is responsible for most of the T 3 in serum. It also catalyzes the 5'-deiodination of 3,3',5'-triiodothyronine (reverse T 3 ), which is the rate-limiting step in the clearance of reverse T 3 , as well as inner-ring deiodination, particularly of T 3 sulfate and T 4 sulfate (Figure 2 and Figure  3 ) 15, 16 . Type II deiodinase acts only on the outer ring and prefers T 4 and reverse T 3 . It is expressed in brain, pituitary gland, brown adipose tissue, keratinocytes, and placenta 13, 17, 18, 19 . Type III deiodinase, present in high amounts in placental tissue, brain, and epidermis, catalyzes the conversion of T 4 to reverse T 3 and T 3 to 3,3'-diiodothyronine (T 2 ) 13, 20 . The activity of type II deiodinase is higher in the chorionic and decidual membranes of the placenta than in the amniotic membranes, whereas type III deiodinase is found mostly in trophoblasts 17 . The mixture of type II and type III deiodinases in the placenta provides for the conversion of T 4 to T 3 and of T 4 and T 3 to reverse T 3 and T 2 , respectively ( Figure 2 and Figure 3 ).
As in other tissues, the activity of type II deiodinase increases when the availability of T 4 decreases 17 . This suggests that deiodinase activity represents a homeostatic mechanism for maintaining T 3 production in the placenta when maternal serum T 4 concentrations are reduced (e.g., during hypothyroidism or iodine deficiency). Most of the beneficial effects of the T 3 generated by the action of maternal type II deiodinase are probably restricted to the placental cells because of the highly active placental type III deiodinase. In fact, placental type III deiodinase seems designed to maintain low serum T 3 concentrations in the fetus while protecting decidual cells from hypothyroidism. The high rate of placental blood flow explains the absence of a measurable difference in serum T 4 and T 3 concentrations between the umbilical artery and vein that might otherwise be anticipated given the high level of type III deiodinase activity in the placenta 21 .
The Placenta as a Barrier to Maternal-Fetal Flux of Thyroid Hormones
The fetal thyroid gland and pituitary-thyroid axis become functional late in the first trimester. Before that time any fetal thyroid hormone must come from the maternal circulation. During most of the first trimester, the amniotic cavity containing the developing embryo is surrounded by the extraembryonic coelom containing coelomic fluid. The extraembryonic coelom is surrounded in turn by the placenta 22 . At 6 to 12 weeks of gestation, the average total T 4 concentrations in maternal serum, coelomic fluid, and amniotic fluid are 11,338, 75, and 1.6 ng per deciliter (146, 0.96, and 0.02 nmol per liter), respectively. Reverse T 3 concentrations are 3.8 and 15 times greater than T 4 concentrations in coelomic and amniotic fluids, respectively 22 . The T 4 concentration in coelomic fluid varies directly with the maternal serum T 4 concentration.
During the second and third trimesters there are marked maternal-to-fetal gradients of free T 4 and T 3 23,24 . For example, at delivery maternal serum free T 3 concentrations are twice those in cord serum 24 . Newborn infants with thyroid agenesis or a total defect in thyroid hormonogenesis have cord serum T 4 concentrations between 20 and 50 percent of those in normal infants, values much lower than in maternal serum 25 . The small amounts of T 4 transferred contribute to T 3 concentrations in the fetal brain and almost certainly minimize the effects of fetal hypothyroidism 26, 27, 28 .
Thyroid Hormones in the Fetus

Development of Fetal Thyroid Function
Fetal thyroid function continues to mature throughout gestation. By 10 weeks after conception fetal thyroid follicles and T 4 synthesis are demonstrable. Increases in pituitary and serum concentrations of thyrotropin during the second trimester coincide with the development of the hypothalamic-pituitary portal circulation, which facilitates the modulation of pituitary thyrotropin secretion by hypothalamic thyrotropin-releasing hormone ( Figure 1 ). The increased secretion of thyrotropin-releasing hormone, despite higher serum free T 4 concentrations, implies immaturity of the negative-feedback system that regulates the secretion of thyrotropinreleasing hormone and thyrotropin (e.g., the threshold or set point for T 4 -induced inhibition of thyrotropin secretion is relatively increased) 28, 29 .
Thyroxine-binding globulin and T 4 are first detectable in fetal serum at 8 to 10 weeks of gestation and increase thereafter until they plateau at 35 to 37 weeks, at which time the serum total T 4 concentration is approximately 10 µg per deciliter (130 nmol per liter) 28, 29, 30 . The progressive increase in serum concentrations of thyroxinebinding globulin presumably reflects maturation of the fetal liver and its responsiveness to estrogen stimulation. As serum concentrations of thyroxine-binding globulin increase in the fetus, there is a progressive increase in the extrathyroidal T 4 pool. In addition, serum free T 4 concentrations rise between 18 to 20 and 35 to 37 weeks of gestation, an increase caused by greater secretion of thyroid hormone. These changes in serum thyrotropin and free T 4 concentrations are caused by increased stimulation of pituitary thyrotropin secretion by thyrotropinreleasing hormone and enhanced thyroidal responsiveness to thyrotropin.
Metabolism of Iodothyronines
The ontogeny of the three deiodinases that catalyze the progressive deiodination of T 4 differs in the developing fetus. Type II and type III deiodinases appear at midgestation, whereas type I deiodinase is not evident until later 13, 29, 30 . Accordingly, fetal serum T 3 concentrations are low (<15 ng per deciliter [0.2 nmol per liter]) before 30 weeks' gestation; they increase gradually to about 50 ng per deciliter (0.7 nmol per liter) at term (Table  1) 20, 24, 28, 29, 30 . Maternal serum values, by contrast, approximate 200 ng per deciliter (2.7 nmol per liter). The preterm increase in fetal serum T 3 concentrations is due to an increase in type I deiodinase activity. Serum concentrations of reverse T 3 , T 4 sulfate, T 3 sulfate, and reverse T 3 sulfate in the umbilical cord at this time are high 31, 32, 33 . The sulfated metabolites accumulate in fetal serum as a result of the very low type I deiodinase activity in fetal tissues and because the sulfated iodothyronines are not substrates for placental type III deiodinase 37 . Although T 3 sulfate does not bind to nuclear T 3 receptors and therefore has no biologic activity, 38 its parenteral administration in rats after thyroidectomy increases serum T 3 concentrations and biologic responses 39 . Thus, T 3 sulfate can be desulfated to T 3 in adult rats, probably by bacterial sulfatases in the gut 40 . The liver, kidney, and brain of adult rats have sulfatase activity, and desulfation of T 3 sulfate to T 3 occurs in the liver and brain of fetal rats 41, 42 . Thus, T 3 sulfate could serve as a local source of T 3 in fetal tissues containing sulfatase. In fetal rats and sheep, brain tissue, brown adipose tissue, pituitary tissue, and perhaps skin contain substantial amounts of type II deiodinase by midgestation (before the increase in serum T 3 concentrations) 43, 44, 45 . This allows for the possibility of the conversion of T 4 to T 3 by local tissues and the potential for varying local-tissue supply of T 3 26,27,43,45 . Type II deiodinase activity increases in fetuses with hypothyroidism, whereas the activities of types I and III deiodinase decrease 27 . These changes favor shunting of T 4 to brain tissues, where deiodination to T 3 is increased and degradation of T 3 is decreased. Thus, although fetal thyroid development is largely independent of maternal influences, even limited transfer of thyroid hormone from mother to fetus may protect a fetus with hypothyroidism 25, 26, 27, 45 . In rat fetuses with hypothyroidism, the increased type II deiodinase activity in association with T 4 derived from the mother can normalize brain T 3 concentrations 26, 27, 45 .
The Importance of Iodothyronines in Amniotic Fluid
In addition to being linked by the umbilical cord, the mother and fetus are linked by the amniotic cavity and amniotic fluid, providing a second pathway for fluid and molecular exchange. The amniotic-fluid volume is the net balance of inflow, consisting of fetal urine and lung fluid, and outflow, consisting of fetal-maternal transamniotic fluid exchange and fetal swallowing 46, 47 . The pattern of iodothyronines in amniotic fluid reflects the effects of type III deiodinase activity in placental and fetal tissues, and the iodothyronine concentrations in amniotic fluid thus reflect both maternal and fetal thyroid hormone metabolism (Figure 3 ) 34, 35, 48, 49 . Reverse T 3 and T 4 and their sulfate conjugates account for more than 95 percent of the total iodothyronines in amniotic fluid ( Table 1 ). The T 4 concentrations increase progressively during gestation, whereas reverse T 3 concentrations decrease.
At term, T 4 concentrations in amniotic fluid are about 0.6 µg per deciliter (8 nmol per liter) (Table 1) , much lower than in maternal or fetal serum. The reverse T 3 concentration, in contrast, is about three times the concentration in maternal serum and one quarter that in cord serum 48, 49 . In fetuses with congenital hypothyroidism, iodothyronine concentrations in amniotic fluid largely reflect maternal thyroid function 48, 49 . is slightly higher than in maternal or fetal serum 34, 35, 49 and the free reverse T 3 concentration is much higher than in maternal serum.
Concentrations of T 3 in amniotic fluid are relatively low (Table 1) , and T 2 concentrations (the product of innerring deiodination of T 3 or outer-ring deiodination of reverse T 3 ) are two to three times higher than in maternal serum and only slightly lower than in fetal serum 34 . These results illustrate the effects of type III deiodination on the maternal T 4 and T 3 entering the amniotic fluid.
The injection of T 4 into amniotic fluid increases thyroid hormone concentrations in amniotic fluid and fetal serum: the injection of 700 µg of T 4 to five pregnant women at term caused a 13-fold increase in amniotic-fluid T 3 concentrations and a 30-fold increase in reverse T 3 concentrations measured 20 to 24 hours later (at the time of delivery), indicating that amniotic fluid T 4 is accessible to both inner-ring and outer-ring deiodinases 36 . Maternal serum T 4 , T 3 , and reverse T 3 concentrations did not increase, but cord serum T 4 and T 3 concentrations increased and the neonatal surge in thyrotropin secretion was blunted. Maternal iodothyronines in amniotic fluid can therefore enter the fetal circulation. Late in gestation, fetal swallowing appears to account for most of the transfer of thyroid hormones from amniotic fluid to the fetal circulation. Early in gestation any transfer of thyroid hormone from amniotic fluid to the fetus would presumably occur transdermally, although such transfer has not yet been demonstrated.
Effects of Thyroid Hormone on the Fetus and Neonate
Thyroid hormones have important roles in embryogenesis and fetal maturation. In rats, maternal thyroid hormone reaches the embryo and fetus from the earliest days of gestation. Moreover, fetal rat tissues, including brain, contain T 4 and T 3 before fetal thyroid hormone is produced 26, 50 . The administration of serum from rats with either hypothyroidism or hyperthyroidism induces malformations in rat-embryo cultures in vitro 51 . Finally, the progeny of pregnant rats with hypothyroidism, when studied as adults, have abnormalities in brain amino acid metabolism, marker enzymes of neuronal and glial cells, and calmodulin-regulated phosphatase activity, although postnatal growth and brain weight are not altered 52, 53, 54 .
In humans living in iodine-deficient areas, maternal hypothyroxinemia is common and is associated with neonatal hypothyroidism and defects in IQ and neurologic function in the offspring 55, 56 . These infants are referred to nosologically as having endemic cretinism. The proximate cause of endemic cretinism is iodine deficiency, but aggravating factors include dietary goitrogens (such as thiocyanate), selenium deficiency, and autoimmune hypothyroidism 55, 56 . The manifestations of endemic cretinism range from goiter or mild mental retardation in euthyroid subjects to severe mental deficiency and neurologic defects in those with variable degrees of hypothyroidism 56, 57 . Two subtypes of endemic cretinism have been described, neurologic cretinism and myxedematous cretinism. People with neurologic cretinism have mental and neurologic abnormalities but appear euthyroid; those with myxedematous cretinism, in contrast, have hypothyroidism 55, 56 . The neurologic abnormalities are similar in both types and presumably represent the combined effects of maternal, fetal, and neonatal hypothyroidism 56, 57 . Neurologic damage in the absence of neonatal hypothyroidism has been postulated to be due to maternal hypothyroxinemia early in gestation 57 .
Both low and normal IQs have been found in the children of women with hypothyroxinemia during pregnancy who live in iodine-sufficient areas (the United States and Japan) 58, 59 . Nuclear T 3 receptors that are relatively saturated with T 3 have been identified in rat and human fetuses early in gestation, particularly in brain tissue, 60, 61, 62, 63 and brain mutation in newborn rats and humans is dependent on thyroid hormone 64, 65 . The presence of occupied T 3 nuclear receptors in brain tissue early in fetal development supports a role for maternal thyroid hormones in the maturation of the brain.
With the advent of newborn screening for congenital hypothyroidism, it has become clear that size, weight, appearance, behavior, extrauterine adaptation, and immediate postnatal development are usually normal in infants with hypothyroidism, even those with thyroid agenesis 66, 67 . The usual manifestations of intrauterine hypothyroidism are increased serum thyrotropin concentrations and low or low-normal serum T 4 concentrations; in addition, bone maturation is delayed at birth in approximately 60 percent 66, 67, 68 . Some newborns may have subtle signs of hypothyroidism, but fewer than 5 percent of cases are diagnosed clinically in the neonatal period. The classic symptoms and signs of hypothyroidism develop progressively during the early weeks and months of extrauterine life. The absence of symptoms and signs in most affected neonates suggests either that metabolism and development in the fetus are not dependent on T 4 or that the small amounts of maternal thyroid hormone in the fetal circulation are sufficient to prevent most clinical manifestations of thyroid deficiency.
Newborn infants with congenital hypothyroidism who are identified by screening programs and treated promptly usually have IQs in the normal range at five to seven years of age, as well as normal growth and development 69, 70, 71 . However, low-normal or occasionally low IQs have been reported in some children with congenital hypothyroidism who had very low serum T 4 and very high thyrotropin concentrations and delayed bone maturation at birth, suggesting that hypothyroidism in utero may lead to some degree of irreversible retardation 71, 72, 73 . Delaying treatment has the same effect on the IQ 72 .
Low serum T 4 concentrations during the first year of treatment in infants with congenital hypothyroidism are also associated with lower IQs at five to seven years of age 70, 73 . These results and information obtained from late-treated infants before the advent of newborn screening suggest that newborn infants with severe hypothyroidism, if untreated, lose 3 to 5 points of IQ monthly during the first 6 to 12 months of life 71, 72, 73, 74, 75, 76, 77 . There is some evidence that more aggressive early treatment may be beneficial; increasing the dose of T 4 in infants with congenital hypothyroidism from 7 to 9 µg per kilogram of body weight per day to 8 to 10 µg per kilogram per day increased the IQ at the age of five to seven years by 4 to 5 points 74 .
Although 
Conclusions
The role of thyroid hormones in fetal growth and development and maturation of the fetal brain remains unclear. Infants with congenital hypothyroidism are born with low serum concentrations of thyroid hormone and high thyrotropin concentrations, but if identified by newborn screening programs and treated appropriately, most will have normal physical and intellectual development. This indicates either that any consequences of intrauterine hypothyroidism are largely reversible or that the fetus is protected in some way from the hypothyroxinemia. There is limited but still important placental transfer of maternal T 4 to the fetus, and recent studies have characterized T 3 nuclear receptors and an iodothyronine deiodinase that catalyzes the conversion of T 4 to T 3 in brain tissue early in fetal life. The current hypothesis is that in fetuses with hypothyroidism, maternal T 4 , by means of compensatory alterations in iodothyronine metabolism, provides sufficient T 3 to the brain to prevent irreversible damage in most instances. The occurrence of neurologic cretinism in areas of severe iodine deficiency (when both fetal and maternal T 4 synthesis are impaired), as well as the results of studies in animals, supports this hypothesis. Nonneurologic fetal tissues appear to have a limited dependence on thyroid hormone.
Pregnancy increases maternal requirements for T 4 , which necessitates a 25 to 50 percent increase in maternal T 4 production in euthyroid women. In women with hypothyroidism or women who live in areas in which iodine deficiency is endemic, fetal brain development is normal if normal maternal concentrations of serum free T 4 are maintained during gestation either by iodine supplementation, where appropriate, or by suitable adjustments of exogenous T 4 treatment. Placental T 4 transfer does not seem sufficient in all cases, however, to protect the brain of fetuses with hypothyroidism, but early intensive postnatal treatment of infants with evidence of intrauterine hypothyroidism will normalize childhood IQs. Whether treatment in utero of the occasional fetus with hypothyroidism is necessary or desirable remains to be demonstrated.
